Drugs for Ureteral Stone Treatment
Author Information
Author(s): Hedlund Petter, Rahardjo Harrina E., Tsikas Dimitrios, Kuczyk Markus A.
Hypothesis
What drug principles can effectively target signaling systems to modulate ureter smooth muscle contractility for treating ureteral stones?
Conclusion
Rho kinase inhibitors should be further explored as a promising pharmacological approach for ureteral stone disease.
Supporting Evidence
- Alpha 1-adrenoceptor antagonists have shown promise in improving stone clearance and reducing hospitalization duration.
- Beta-AR agonists have been evaluated but show insufficient evidence for pain management in renal colic.
- Phosphodiesterase inhibitors have demonstrated better expulsion rates compared to placebo in some studies.
Takeaway
This study looks at different drugs that can help move kidney stones through the ureter by relaxing the muscles. Some drugs work better than others.
Methodology
The article reviews various drugs evaluated in vitro, in vivo, and in clinical settings for their ability to facilitate the passage of ureteral stones and relieve pain.
Potential Biases
Concerns about variability in efficacy and quality of evidence from trials were noted.
Limitations
The evidence for some drug therapies is variable and not robust, indicating a need for further studies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website